Johannes Hans W. Louwerenburg

Showing 1-8 of 8 articles

Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT

Zocca P, van der Heijden LC, Kok M, Löwik M, Hartmann M, Stoel M, Louwerenburg H, de Man F, Linssen GCM, Knottnerus I, Doggen CJM, van Houwelingen K, von Birgelen C

November 20, 2017 | 10.4244/EIJ-D-17-00634

Coronary interventions

Value of the SYNTAX score for periprocedural myocardial infarction according to WHO and the third universal definition of myocardial infarction: insights from the TWENTE trial

Tandjung K, Lam MK, Sen H, de Man F, Louwerenburg H, Stoel M, van Houwelingen K, Linssen GCM, van der Palen J, Doggen CJM, von Birgelen C

July 20, 2016 | 10.4244/EIJY15M08_01

Coronary interventions

Patient preference regarding assessment of clinical follow-up after percutaneous coronary intervention: the PAPAYA study

Kok M, von Birgelen C, Lam MK, Löwik M, van Houwelingen K, Stoel M, Louwerenburg H, de Man F, Hartmann M, Doggen CJM, van Til J, IJzerman M

April 20, 2016 | 10.4244/EIJY15M10_06

Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial

Lam MK, Tandjung K, Sen H, Basalus M, van Houwelingen K, Stoel M, Louwerenburg H, Linssen GCM, Said S, Nienhuis M, de Man F, van der Palen J, von Birgelen C

June 19, 2015 | 10.4244/EIJV11I2A32

Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial

Löwik M, Lam MK, Sen H, Tandjung K, van Houwelingen K, de Man F, Stoel M, Louwerenburg H, Linssen GCM, Doggen CJM, von Birgelen C

March 20, 2015 | 10.4244/EIJY14M08_11

Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trial

Sen H, Lam MK, Tandjung K, Basalus M, de Man F, Louwerenburg H, Stoel M, van Houwelingen K, Löwik M, Linssen GCM, Said S, Nienhuis M, Verhorst P, van der Palen J, von Birgelen C

October 20, 2014 | 10.4244/EIJV10I6A117

Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and XIENCE V drug-eluting stents

Sen H, Tandjung K, Basalus M, L M, van Houwelingen K, Stoel M, Louwerenburg H, de Man F, Linssen GCM, Nijhuis R, Nienhuis M, Verhorst P, van der Palen J, von Birgelen C

October 26, 2012 | 10.4244/EIJV8I6A104

Usefulness and safety of the GuideLiner catheter to enhance intubation and support of guide catheters: insights from the Twente GuideLiner registry

de Man F, Tandjung K, Hartmann M, van Houwelingen K, Stoel M, Louwerenburg H, Basalus M, Sen H, Löwik M, von Birgelen C

July 27, 2012 | 10.4244/EIJV8I3A52

1

Latest news

Robotics, AI and Imaging State of The Art; Bleeding Risk and Mortality in CAD; Treating Refractory Angina by Coronary Sinus Narrowing; and more

September 20, 2021

STATE OF THE ART

Robotics, imaging, and artificial intelligence in the catheterisation laboratory

Rafael Beyar et al.

September 20, 2021

ViV TAVI vs repeat SAVR

Monil Majmundar et al.

September 15, 2021

Thrombectomy for ischaemic stroke

Christopher A. Rajkumar et al.

September 10, 2021

Walking the tightrope between ischaemia and bleeding

Michelle L. O’Donoghue et al.

September 20, 2021

Microvascular dysfunction endotypes and outcomes

Christos V. Bourantas et al.

September 20, 2021

Coronary sinus reducer therapy for refractory angina: is it ready for prime time?

Michael Foley et al.

September 20, 2021

Valvular disease